Epredia, a global leader in precision cancer diagnostics, and Aiforia, a 
medical software company providing Artificial Intelligence (AI) based solutions 
for image analysis in pathology, have announced today that they have entered 
into a commercial distribution agreement for Aiforia's comprehensive portfolio 
of workflow enhancing solutions which enable pathologists to harness the power 
of deep learning AI for image analysis. 

Photo - https://mma.prnewswire.com/media/1537009/Clinical_Ki67_IA.jpg 
Logo - https://mma.prnewswire.com/media/1458465/Epredia_Logo.jpg


Under the terms of this agreement, Epredia has been appointed as a global 
distribution partner for Aiforia's portfolio of preclinical and clinical 
pathology tools, including segment exclusivity for distribution in Japan, 
Germany, UK, Italy, Spain, Sweden, Norway, Denmark, Iceland, France and the 
USA. From Summer 2021, Epredia will begin to commercialize the Aiforia 
portfolio of AI solutions. These solutions will be available as part of 
Epredia's comprehensive digital pathology portfolio that already features the 
best-in-class CE-marked 3DHistech P1000 WSI scanner*. 

Aiforia aims to equip pathologists with AI-powered, secure, and scalable 
cloud-based software for high precision image analysis that can be used in 
preclinical research and clinical diagnostics. Their solutions aim to enhance 
the speed and accuracy of pharmaceutical drug development and cancer 
diagnostics using intuitive, AI-powered software. Aiforia's software currently 
has over 3,000 pathologists and scientists as users in over 50 countries. 

Aiforia recently announced the CE-IVD marking for its Clinical AI Model for 
Breast Cancer: Ki67, a widely used key biomarker in breast cancer diagnostics, 
as part of the company's upcoming Clinical Suites. The Aiforia Clinical Suites 
are under development to support the diagnosis of some of the world's most 
prevalent cancers such as breast, lung, prostate, and more. The Suites, 
intended for release and regulatory filings over the coming years, are 
portfolios of powerful tools enabling pathologists to harness the power of AI 
to support them in accelerating sample review, enhancing diagnostic accuracy, 
and ultimately in improving patient outcomes.

Aiforia's offering for preclinical assessment consists of bespoke AI model 
development services backed by Aiforia's in-house science team using an 
intuitive cloud-based platform, catering to a wide range of therapy areas. Over 
400 AI models for preclinical research have already been developed using 
Aiforia's solutions.

"This alliance with Aiforia to commercialize their highly innovative portfolio 
of AI-based digital pathology solutions is another exciting step in building 
our presence in this growing area of cancer diagnostics," explained John 
Sweeney, President, Epredia. "We are pleased to be adding the Aiforia offering 
to our portfolio of digital pathology solutions which now include cutting edge 
AI software from the largest players in the field bundled with our portfolio of 
best in class whole slide imaging scanners developed by 3DHistech. The product 
development expertise of Aiforia that has gone into these solutions ideally 
complements our global commercial reach and will enable us to bring their 
solutions to more pathologists across the world."

"With their global presence in the pathology market and our expertise in 
delivering AI-based solutions for pathologists, Epredia is the ideal commercial 
partner to help us broaden the international reach of Aiforia's powerful AI 
software to pathologists working in clinical diagnostics and preclinical drug 
development," explained Jukka Tapaninen, Chief Executive Officer of Aiforia. 
"Our mission is to become a global leader in AI-assisted image analysis to 
improve the efficiencies of healthcare systems and enable better patient 
outcomes." 

* Regulatory requirements for the 3DHistech P1000 scanner and Aiforia's 
pathology solutions vary by country, please consult with your commercial 
partner to confirm the availability and approved use of the scanner and 
Aiforia's pathology solutions in your country.

SOURCE:  Epredia